- covid-19 patients with critical manifestations. - sepsis. - acute respiratory distress syndrome (ards). - decompensated liver disease (child-pugh class b or c disease). - chronic renal impairment. - patients with blood diseases (severe anemia, thalassemia, itp, leukemia ….). - ischemic heart disease within the last 6 months. - chronic pulmonary disease. - malignancy. - pregnancy or breastfeeding. - hypersensitivity to sofosbuvir or ribavirin. - patients with organ transplant. - unwilling to participate in our study

- covid-19 patients with critical manifestations. - sepsis. - acute respiratory distress syndrome (ards). - decompensated liver disease (child-pugh class b or c disease). - chronic renal impairment. - patients with blood diseases (severe anemia, thalassemia, itp, leukemia ….). - ischemic heart disease within the last 6 months. - chronic pulmonary disease. - malignancy. - pregnancy or breastfeeding. - hypersensitivity to sofosbuvir or ribavirin. - patients with organ transplant. - unwilling to participate in our study